PERSONALIZED MEDICINE: PRESENTING “DIANA”, THE DIAGNOSTIC BOOTH THAT SIMPLIFIES CLINICAL EXAMS AND MONITORS THE EFFECTIVENESS OF TREATMENTS
The project stems from the synergy between Antares Vision Group, Isinnova and the National Research Center “Development of gene therapy and drugs with RNA technology”. The first prototype will be ready at the end of June 2025
Travagliato, (Brescia), 17 December 2024 – An innovation that promises to revolutionize medical diagnostics. It’s called DIANA (Diagnostica Intelligente per Analisi Non Invasiva Avanzata – Intelligent diagnostics for advanced non-invasive analyses) and is the result of a partnership between Antares Vision Group, Italian multinational, leading provider in Track & Trace systems and quality control, and Isinnova, a Brescia-based SME, which enables and makes technological innovation accessible, with the strategic support of the National Research Center “Development of gene therapy and drugs with RNA technology” funded by the NRRP.
DIANA is a booth that combines advanced non-invasive technologies, and represents a real step towards personalized medicine, seeking to improve the quality of treatments and patients’ lives. The objective is to accelerate and simplify diagnoses, monitor the effectiveness of treatments in real time, and support the development of bespoke drugs for the patient, offering a diagnostic platform able to perform over 60 non-invasive exams in just 15 minutes. The exams, which include tests on electrical-brain activity, cardiac activity, blood composition, body composition, electrical-muscular activity and lung capacity, provide a complete and personalized picture of a patient’s health, reducing the time and costs of traditional analyses.
“To accomplish this project, we used technologies that were already known or were at an experimental stage, and we combined them to create DIANA, thanks to the efforts of our team of experts – state Cristian Fracassi and Marco Silvestri from ISINNOVA, CEO and head of the Diana project respectively. The objective of the booth, which we would like to create different versions of, based on the area of application, is not to replace doctors, but to speed up the work of health professionals”.
“The potential of DIANA combined with gene therapy protocols can help us to monitor the effectiveness of drugs with RNA technology in real time, which we are developing in our role as National Research Center – states prof. Rosario Rizzuto, President of the National Research Foundation for the development of gene therapy and drugs with RNA technology. Supporting a technology like DIANA’s means reducing research time, simplifying diagnostic steps, but above all finding increasingly accurate and sustainable treatments”.
“DIANA represents a paradigm shift, and paves the way for a faster, more efficient and above all personalized medicine, focused on the patient – explains Alberto Albertini, Innovation Center Director of Antares Vision Group. Technology makes it possible to apply scientific research for the benefit of everyone’s health. Moreover, the partnership between the three entities involved in the project, demonstrates how synergy between research bodies, companies and universities can be transformed into real solutions for medical and technological progress”.
The first prototype of DIANA, called DIANA-ATMP, will be ready mid-2025, and will be used at the National RNA & Genetherapy Center to monitor patients undergoing gene and advanced pharmacological treatments.
DIANA’s contribution will be fundamental in the data collection stage, as it will speed up the process of acquiring and integrating information in a short timeframe, at a high level of quality, also as regards remote healthcare with respect to large medical research centers. The technology will enable different sources to be combined in a single integrated system, simplifying data access and analysis for doctors. This approach, together with the opportunity to personalize treatment plans based on the specific characteristics of each patient, will enable more targeted and effective treatments to be offered, as well as creating a more complete archive to study specific diseases.
Antares Vision Group is working with Isinnova on industrializing innovative solutions, and in 2022, acquired a 15% stake of the Brescia-based SME’s share capital. The Italian multinational is also a technological partner of excellence in the research and innovation projects funded by the European Union, and in 2023, signed an agreement with the National Research Center “Development of gene therapy and drugs with RNA technology” as founder, which envisages a commitment to make its solutions available in digital healthcare, smart digital innovation, software platforms, digital twin systems, technologies for traceability and serialization, origin and certification of drugs and products, quality inspections with computer vision, IoT sensors and data analysis, also thanks to Artificial Intelligence.